Skip to content

Dnmt1 Related Disorder Cn381527

Published: July 22, 2026Updated: August 20, 2026

A neurological disorder caused by mutations in the DNMT1 gene, affecting the nervous system. It can cause progressive movement problems and cognitive changes. Management focuses on symptom support and multidisciplinary care.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
G40.909
ICD-11
8A00.0
Body system
neurologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Seizures

Cognitive decline

(neurologic)

Generalized symptoms

(neurologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Hearing loss

(neurologic)

Ataxia

(neurologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Comprehensive Neurologic Surveillance

Regular monitoring of cognitive function, cerebellar signs, neuropathy progression, and autonomic symptoms to guide treatment adjustments and anticipate complications.

monitoring
2

Targeted drug therapy with dose adjustment

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Balance and Gait Training

Specialized physical therapy focusing on balance, coordination, and gait training to reduce fall risk and maintain functional mobility as ataxia progresses.

physical_therapy

Additional treatment options

Symptomatic Symptom Management

Targeted medications for specific symptoms such as spasticity, neuropathic pain, or autonomic dysfunction as they arise during disease progression.

medication

Fall Prevention Strategies

Home modification, assistive devices, and environmental adaptations to reduce injury risk from falls, which are common due to progressive ataxia and sensory neuropathy.

lifestyle

Neuropsychological Evaluation

Baseline and follow-up cognitive assessments to monitor for dementia development, guide educational or vocational planning, and inform care decisions.

procedure

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Dnmt1 Related Disorder Cn381527?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Medication Comparisons

Compare medications used to treat Dnmt1 Related Disorder Cn381527. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy